![]() |
Image: Leppä lab |
Analyzed in the study were blood samples of lymphoma patients treated in a Nordic Lymphoma Group trial, which were collected before, at the mid-point of and after treatment.
Increasingly accurate diagnostics and more effective therapies
“The analysis of ctDNA in the blood samples revealed significant diagnostic features, not all of which were found in regular tumour biopsies,” says Professor Sirpa Leppä from the University of Helsinki and the HUS Comprehensive Cancer Center.
The researchers found that the concentration of ctDNA in blood before therapy varied considerably between patients and was comparable to the combined volume of the malignant tumors.
“Patients with the highest ctDNA levels at the time of lymphoma diagnosis had the poorest survival probability,” explains MD and PhD student Leo Meriranta.
At the same time, changes in ctDNA concentration during therapy reflected treatment responses in that the patients whose lymphoma was unaffected by the treatment were distinguished from other patients by the ctDNA analyses carried out using the follow-up blood samples.